Home
News
Screeners
Insights
Ishita Drugs & Indus
76.
20
+2.20
(+2.97%)
Market Cap
₹22.76 Cr
PE Ratio
31.36
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.97%
1M
+2.97%
6M
0.00%
1Y
-6.39%
5Y
+94.88%
View Company Insights
Latest news about Ishita Drugs & Indus
Ishita Drugs re-appoints Abha Agrawal as director post-75 age limit
1 day ago
Mrs. Abha Agrawal re-appointed as director with 86.92% votes despite age cap. Jaymin Shah & Associates re-appointed as statutory auditors for FY27. FY26 financial statements adopted with 99.99% support from shareholders. Related party transactions with Ishita Pharmaceuticals approved by majority.
Ishita Drugs closes trading window until Q2FY27 results declaration
7 days ago
Ishita Drugs enters ₹11.75 crore loan deal with HDFC Bank for facility upgrade
Sep 22, 2026
Ishita Drugs sets Sep 30 AGM for related-party deals, director re-appointment
Aug 31, 2026
Ishita Drugs & Industries Q1 Results: Net profit falls 24% YoY to ₹23 lakh
Aug 08, 2026
More news about Ishita Drugs & Indus
24
Jun 26
Ishita Pharma raises stake to 1.10% in Ishita Drugs
Ishita Pharmaceuticals, a related party, acquired 223 shares in Ishita Drugs & Industries via an open market transaction on June 22, 2026. This purchase increased the acquirer's stake to 1.10% from 1.09%, with the total holding reaching 32,920 shares. The disclosure was filed with BSE Limited on June 24, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
30
May 26
Ishita Drugs FY26 net profit falls to ₹77.85 lakh
Ishita Drugs & Industries Limited reported a decline in net profit to ₹77.85 lakh for FY26 from ₹86.81 lakh in FY25, with revenue from operations decreasing to ₹1466.02 lakh. The board approved the audited results on May 30, 2026, showing an EPS of ₹2.60. Total assets reduced to ₹1260.37 lakh, while operating cash flow turned positive at ₹391.93 lakh.
13
Apr 26
Ishita Drugs & Industries Ltd Confirms Non-Applicability of SEBI Regulation 32(1) for FY26
Ishita Drugs & Industries Ltd notified BSE Limited that SEBI Regulation 32(1) regarding statement of deviation from proceeds is not applicable for FY26 ended 31st March, 2026. The company confirmed it did not raise funds through public issue, rights issue, preferential issue, or QIP during this period. The communication was signed by Managing Director Jagdish Agrawal and submitted on 13th April, 2026.
10
Apr 26
Ishita Drugs and Industries Limited Submits SEBI Compliance Certificate for Q4FY26
Ishita Drugs and Industries Limited submitted its Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for Q4FY26 ended March 31, 2026. The certificate from RTA Bigshare Services Private Limited confirms no securities were received for dematerialization during the quarter. This regulatory filing demonstrates compliance with SEBI's quarterly reporting requirements for dematerialization activities.
27
Feb 26
Ishita Drugs & Industries: Related Party Makes Second Share Acquisition
Ishita Pharmaceuticals, a related party of Ishita Drugs & Industries Ltd, made a second share acquisition of 390 equity shares through open market purchase on February 26, 2026. This increased their total holding to 32,642 shares representing 1.09% of the company's equity, up from the previous 1.08% stake.
14
Feb 26
Ishita Drugs and Industries Limited Files SEBI Disclosure for Substantial Acquisition
Ishita Drugs and Industries Limited has filed a disclosure under SEBI Regulation 29(2) for substantial acquisition involving Ishita Pharmaceuticals as acquirer. The filing mentions 30,550 shares and indicates the acquirer is a related party to the target company. The disclosure, digitally signed by key personnel, demonstrates regulatory compliance for the transaction involving shares listed on BSE Limited.
07
Feb 26
Ishita Drugs Q3FY26 Results: Revenue Falls 24% to ₹313.62 Lakhs
Ishita Drugs & Industries Limited announced Q3FY26 results showing revenue decline of 24% to ₹313.62 lakhs and net profit drop of 35% to ₹15.55 lakhs. However, nine-month performance demonstrated resilience with 11.23% revenue growth and the company invested ₹165 lakhs in manufacturing facility upgrades for Revised Schedule M compliance.
30
Jan 26
Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results
Ishita Drugs & Industries Ltd has scheduled a board meeting for February 07, 2026, to approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting complies with SEBI Regulation 29 requirements. A trading window closure is in effect from January 1, 2026, until 48 hours after results announcement, following insider trading prevention protocols.
31
Dec 25
Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares
Jagdish Agrawal, promoter of Ishita Drugs & Industries Ltd, acquired 254 equity shares worth ₹2,540 through open market transactions on December 29, 2025. His shareholding increased marginally from 4.40% to 4.41%, with total holding rising from 131,555 to 131,809 shares. The acquisition was disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations. The company's equity share capital remains stable at ₹2.99 crores comprising 2,990,300 shares of ₹10 each.
10
Dec 25
Ishita Pharmaceuticals Increases Stake in Ishita Drugs & Industries to 1.02%
Ishita Pharmaceuticals has increased its stake in Ishita Drugs & Industries to 1.02% through an additional acquisition of 560 shares worth Rs. 10.00 each on December 08, 2025. This follows earlier investments, bringing the total holding to 30,550 shares from the previous 29,990 shares, representing continued strategic interest between the related pharmaceutical companies.
11
Nov 25
Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade
Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.
Ishita Drugs & Indus
76.
20
+
2.
20
(+
2.
97
%)
1 Year Returns:
-6.39%
Industry Peers
Sun Pharmaceutical
1,801.00
(-
0.
86
%)
Divis Laboratories
9,249.00
(-
0.
46
%)
Torrent Pharmaceuticals
4,767.30
(-
0.
68
%)
Zydus Life Science
1,145.70
(-
1.
40
%)
Cipla
1,344.00
(-
0.
15
%)
Laurus Labs
1,984.00
(+
0.
20
%)
Mankind Pharma
2,535.00
(+
1.
25
%)
Dr Reddys Laboratories
1,206.20
(-
2.
17
%)
Aurobindo Pharma
1,676.80
(+
0.
29
%)
Lupin
2,031.20
(+
0.
05
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar